Jim Simons
TOVX icon

Jim Simons’s Theriva Biologics TOVX Stock Holding History

Jim Simons’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9K Buy
+63,710
New +$18.9K ﹤0.01% 3110
2024
Q3 		– Sell
-4,148
Closed -$24.5K – 3892
2024
Q2 		$24.5K Buy
4,148
+1,408
+51% +$12.3K ﹤0.01% 3365
2024
Q1 		$32K Buy
2,740
+372
+16% +$4.35K ﹤0.01% 3546
2023
Q4 		$25K Buy
2,368
+200
+9% +$2.46K ﹤0.01% 3563
2023
Q3 		$29K Buy
2,168
+620
+40% +$9.43K ﹤0.01% 3477
2023
Q2 		$39K Buy
1,548
+160
+12% +$2.82K ﹤0.01% 3657
2023
Q1 		$24K Buy
1,388
+88
+7% +$1.82K ﹤0.01% 3797
2022
Q4 		$15K Buy
1,300
+32
+3% +$581 ﹤0.01% 4009
2022
Q3 		$31K Buy
1,268
+392
+45% +$15K ﹤0.01% 3840
2022
Q2 		$47K Buy
876
+446
+104% +$25.5K ﹤0.01% 4004
2022
Q1 		$31K Buy
430
+348
+424% +$23.7K ﹤0.01% 3969
2021
Q4 		$6K Buy
+82
New +$7.73K ﹤0.01% 3859
2021
Q1 		– Sell
-4,951
Closed -$474K – 3706
2020
Q4 		$474K Buy
4,951
+1,512
+44% +$132K ﹤0.01% 2842
2020
Q3 		$408K Sell
3,439
-119
-3% -$15.9K ﹤0.01% 2891
2020
Q2 		$455K Buy
3,558
+803
+29% +$76.5K ﹤0.01% 2910
2020
Q1 		$221K Buy
2,755
+428
+18% +$48.7K ﹤0.01% 3078
2019
Q4 		$295K Buy
2,327
+321
+16% +$34.2K ﹤0.01% 3075
2019
Q3 		$228K Buy
2,006
+260
+15% +$31.4K ﹤0.01% 3110
2019
Q2 		$240K Buy
1,746
+139
+9% +$20K ﹤0.01% 3255
2019
Q1 		$273K Buy
1,607
+204
+15% +$33.8K ﹤0.01% 3123
2018
Q4 		$196K Buy
1,403
+1,222
+675% +$290K ﹤0.01% 3140
2018
Q3 		$118K Buy
+181
New +$200K ﹤0.01% 3229
2017
Q2 		– Sell
-3
Closed -$14K – 3363
2017
Q1 		$14K Buy
+3
New +$20.9K ﹤0.01% 3182

Other funds holding TOVX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jim Simons's TOVX Position: Q2 2026 in Review

Jim Simons opened a new position in Theriva Biologics (TOVX) in Q2 2026: 63,710 shares worth $15.9K. The stake represents ﹤0.01% of the portfolio and ranks #3110 among its holdings. This is a return to the name: Jim Simons previously reported a position in TOVX as recently as Q2 2024.

Jim Simons first reported a position in TOVX in Q1 2017 and has held it in 23 quarters since. The position peaked at $474K in Q4 2020. 15 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.

  • Jim Simons held 63,710 shares of Theriva Biologics worth $15.9K as of Q2 2026.
  • Theriva Biologics was a new Jim Simons position in Q2 2026.
  • Theriva Biologics made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #3110 holding.
  • Jim Simons first reported a position in Theriva Biologics in Q1 2017 and has held it in 23 quarters since.
  • Jim Simons's Theriva Biologics position peaked at $474K in Q4 2020.
  • 15 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.